JP Morgan Chase’s Hemab Therapeutics COAG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30.4M Sell
932,857
-219,563
-19% -$9.6M ﹤0.01% 1856
2026
Q2
$42.3M Buy
+1,152,420
New +$31.8M ﹤0.01% 1599

Other funds holding COAG

JP Morgan Chase's COAG Position: Q3 2026 in Review

JP Morgan Chase reduced its Hemab Therapeutics (COAG) stake by 19% in Q3 2026, selling an estimated $9.6M and leaving 932,857 shares worth $30.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

JP Morgan Chase first reported a position in COAG in Q2 2026 and has held it in 2 quarters since. The position peaked at $42.3M in Q2 2026. 63 funds tracked by Wall St. Rank hold COAG as of Q3 2026.

  • JP Morgan Chase held 932,857 shares of Hemab Therapeutics worth $30.4M as of Q3 2026.
  • JP Morgan Chase sold 219,563 Hemab Therapeutics shares in Q3 2026, an estimated $9.6M.
  • Hemab Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #1856 holding.
  • JP Morgan Chase first reported a position in Hemab Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • JP Morgan Chase's Hemab Therapeutics position peaked at $42.3M in Q2 2026.
  • 63 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.